Company

[ News ] [ Our People ] [ Our Partners ]

Our People

[ Management Team ] [ Scientific Advisors ] [ Board of Directors ]

Management Team

Erich Mohr, Ph.D., R.Psych.
Chairman & Chief Executive Officer
Founder of MedGenesis Therapeutix Inc.

Erich Mohr, Ph.D., R.Psych, is the Chairman and CEO of MedGenesis Therapeutix Inc. which he founded in 2005. Dr. Mohr, a Professor of Medicine and Psychology at the University of Ottawa until 1997 has over 21 years of experience in experimental therapeutics of CNS disorders. He is credited with over 150 publications, books, book chapters and abstracts and has edited the Handbook of Clinical Trials: The neurobehavioral approach. Dr. Mohr has chaired and/or served on several regulatory advisory panels for the approval of new products for the treatment of neurodegenerative disease and is the former Chairman and Chief Executive Officer of CroMedica Global Inc. (merged with PRA International in 2002) and the co-founder of several biotechnology companies. His most recent position was with PRA International, where he served as Chief Scientific Officer. PRA is one of the top 5 contract research organizations in the world and is listed on NASDAQ. Over the course of his career, Dr. Mohr has overseen and/or participated in dozens of clinical development programs resulting in a number of approved drugs.

H. Christian Fibiger, Ph.D.
Chief Scientific Officer

H. Christian Fibiger, Ph.D. received his B.Sc. in Chemistry and Psychology from the University of Victoria in 1966 and his Ph.D. in Psychopharmacology from Princeton University in 1970. Dr. Fibiger was formerly the Chief Scientific Officer for Biovail Laboratories International (now Valeant). From 2003 until 2007 he was Vice President and Global Head of Neuroscience at Amgen. In this position he was responsible for Amgen’s worldwide Neuroscience discovery efforts ranging from early exploratory research through clinical candidate selection. Before joining Amgen in 2003, Dr. Fibiger served as Vice President of Neuroscience Discovery Research and Clinical Investigation, and LRL Europe at Eli Lilly and Company. Before moving to Lilly in 1998, Dr. Fibiger served as Professor and Head of the Division of Neurological Sciences and Chair of the University Graduate Program in Neuroscience at the University of British Columbia in Vancouver. He has made numerous contributions to neuroscience research and, during his academic career, was among the top 100 most cited scientists in neuroscience. He has received many honors for his research contributions, including the Clark Institute Prize in Psychiatry, the Heinz Lehmann Award of the Canadian College of Neuropsychopharmacology, the Killam Research Prize, the Gold Medal in Health Sciences from the Science Council of British Columbia and the Tanenbaum Distinguished Scientist Award in Schizophrenia Research. He is a Fellow of the American College of Neuropsychopharmacology (ACNP). Dr. Fibiger serves on the editorial boards of several journals in the field of neuroscience and has been coeditor of Neuropsychopharmacology, the official publication of the American College of Neuropsychopharmacology.

Greg A. Johnson
Chief Operating Officer

Mr. Johnson has 17 years of clinical research experience, and is a recognized expert in electronic data capture and the implementation and use of computerized systems in a clinical research setting. Before joining MedGenesis, Mr. Johnson held several senior positions at PRA International including Vice President, Operations for the Americas, and Vice President, Global Data Management. During his tenure at PRA International, he was responsible for the successful management of dozens of global clinical programs in several therapeutic areas. In addition to his expertise in clinical data management, Mr. Johnson has wide-ranging experience in strategic planning, project management and operations management. Mr. Johnson has a M.Sc. in Clinical Research, holds Project Management Professional (PMP) certification, and is a Fellow in the Institute of Clinical Research (FICR).

Michael Lincoln
Chief Financial Officer

Mr. Michael Lincoln has over 21 years of experience in the pharmaceutical and biotechnology industries with a proven track record of successfully managing the growth and development of biotech companies and creating partnerships. Previous experience includes being the Chief Financial Officer of a public biotech company and participation in the Initial Public Offering and the raising of capital. In addition, Mr. Lincoln has initiated and participated in the completion of multiple partnerships including a technology partnership with a large multinational, M&A activity, joint ventures, and the licensing of numerous branded products. Prior to joining MedGenesis, Mr. Lincoln was a Senior Executive at Transition Therapeutics Inc. and the Altimed Pharmaceutical Company and has held various management positions at Merck Frosst Canada Inc. He is a co-founder and past Chair of the Canadian Healthcare Licensing Association and has a Master of Business Administration degree and is a Certified Management Accountant.

Matthias Luz, M.D.
Chief Medical Officer

Dr. Luz is a board-certified anesthesiologist and intensive care physician with an extensive background in epidemiology, clinical trial methodology and global regulatory affairs. In addition to six years of clinical experience, Dr. Luz has 17 years of global product development experience in the biopharmaceutical and clinical research industry. Before joining MedGenesis, Dr. Luz was the Vice President and Head, Global Product Development Services for PRA International. In this capacity, Dr. Luz led a worldwide team of senior scientists and accomplished drug development experts involved in the design and implementation of high quality development programs from pre-IND to Phase III and submission. During a previous tenure at Behringwerke/Hoechst Marion Roussel/Aventis, Dr. Luz led the team that brought Refludan^®, the first therapeutic for heparin-induced thrombocytopenia, to market worldwide. Dr. Luz also held other senior positions at Knoll/Abbott and Cardion.

Page last updated: 18 April 2011